Seroprevalence of Infection-induced SARS-CoV-2 Antibodies (COVID-19) in Children

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

4032 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-03-13

Study Completion Date

2022-11-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

It is unknown what proportion of children have been exposed to SARS-CoV-2 and how many have antibodies among children seeking medical care for non-Covid-19 related conditions.

The aim of this study is to identify children with IgG antibodies to SARS-CoV-2 who have not been previously diagnosed and are presumed/confirmed Covid-19 negative, then determine the level of immunity in this population which could inform further decisions about covid-19 vaccine strategies for children

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Immunity Against SARS-CoV2 in Children and Their Parents / COVID-19

NCT04355533

COVID-19 Infection

COMPLETED NA

Immunogenicity Against SARS-CoV-2 in COVID-19 Close Contacts

NCT05094635

Covid19 Vaccine Reaction

UNKNOWN

SeroCovid<19: Covid-19 Seroconversion in Tertiary Pediatric Patients

NCT04615000

Covid19 Children, Only

COMPLETED

COVID Infection in Pediatric Surgical Patient

NCT05898529

COVID-19

RECRUITING

Seroprevalence of SARS-Cov-2 Antibodies in Children

NCT04347408

COVID Corona Virus Infection Multisystem Inflammatory Syndrome in Children

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Enrolled participants will have a survey about demographic information, history of previous suspected/confirmed Covid-19 infection or exposed to SARS-CoV-2, Covid-19 vaccination status. For participants aged less than 12 months, participants' mothers' status of Covid-19 vaccination and/or previous infection will be recorded. Participants will then complete serologic testing for SARS-CoV-2 IgG antibodies using residual plasma specimens collected/stored for routine laboratory tests on the date of enrollment. The study will characterize the prevalence of antibody positivity in this population and assess whether there is a correlation between demographic characteristics and antibodies levels.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SARS-CoV-2 IgG Antibody testing

IgG Antibody testing for previous exposure to SARS-CoV-2

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≤ 18 years old.
* Seeking medical care at Vietnam National Children's Hospital for any condition not related to acute Covid-19
* Have not been previously diagnosed and are presumed/confirmed COVID-19 negative
* Have blood specimens collected for any routine biochemistry test on the date enrollment